• Synergy of pathological diagnosis and gene analysis by leading-edge technology based on quality control and quality assurance
  • Synergy of pathological diagnosis and gene analysis by leading-edge technology based on quality control and quality assurance
  • Synergy of pathological diagnosis and gene analysis by leading-edge technology based on quality control and quality assurance
  • Synergy of pathological diagnosis and gene analysis by leading-edge technology based on quality control and quality assurance
  • Synergy of pathological diagnosis and gene analysis by leading-edge technology based on quality control and quality assurance
  • Synergy of pathological diagnosis and gene analysis by leading-edge technology based on quality control and quality assurance
  • Synergy of pathological diagnosis and gene analysis by leading-edge technology based on quality control and quality assurance
  • Synergy of pathological diagnosis and gene analysis by leading-edge technology based on quality control and quality assurance
  • Synergy of pathological diagnosis and gene analysis by leading-edge technology based on quality control and quality assurance

Company Information

General Information

Name of Company Eurofins GeneticLab Co., Ltd.
Head Office 28-196, Nishi 15, Kita 9 Jo, Chuo-ku, Sapporo-shi, Hokkaido 060-0009 Japan
Date Established September 1, 2000
Capital Yen 100 Million

Corporate Profile

Mission statement

　Step forward with the technological innovation in medicine

Management principle

　We strive for making our company creative and active, and contribute to medical development making the most of our teamwork based on wisdom and practice.

History

　Eurofins GeneticLab was founded in 2000 as an industry-university cooperation venture company from a national university, and started a business enterprise with development of gene-analysis technology as our primary business. Eurofins GeneticLab merged with a pathological examination company in 2003 and has strengthened the business foundation. Then, Eurofins GeneticLab has grown into the clinical test trust business having the pathological examination services as the core business, and now, companion diagnostic-related technology services toward the personalized medicine have become the mainstay of the company.

Strength of Our Business

Pathological Analysis Technology
Pathological business department processes human samples including biopsy specimens, surgical specimens, cytologic specimen fluid, and the animal samples into appropriate preparation slides, and makes pathological diagnoses by full-time medical specialists of pathology.
In addition to usual pathological diagnosis, rapid diagnosis at surgery, cytological diagnosis, HPV typing, one-day pathology and renal pathological diagnosis, it has become possible to implement wide range of advanced pathological analysis by introducing leading-edge medical technologies.
Dynamic Medical Technology
Dynamic Biomedicals Business technology department has been making following achievements, development of the medical treatment prognostic optimal genetic diagnosis kits of incurable diseases and HPV genotyping kit, various transcriptome analyses by GeneChip® devices, search and evaluation of biomarker proteins in the very-small-quantity level by suspension array technology. And the analysis technologies are applicable to various samples including peripheral blood, specific tissues, tumor cells and animal cells.
The Innovation by
Fusion of
Pathological Analysis
Technology and
Leading-edge Medical
Technology		 　Eurofins GeneticLab is able to offer one-stop services of high quality analysis, multiplex fluorescence staining of multiple target molecules, quantitative analysis of target molecules, ISH analysis, selective tissue extraction by a laser microdissectin and cell/tissue micro array, widely from experimental animals to human biopsy or surgical specimens by fusion of the latest analysis technologies that pathological department and leading-edge medical technology department have.
　Eurofins GeneticLab provides advice and recommendations on the research strategy of clients by the researchers who became skilled in the technologies, furthermore, while developing new diagnostic techniques and diagnostic products of malignant tumors, refractory disorders and infections, it practices innovation of diagnosis and medical technology toward the appropriate and effective personalized medicine by genetic analyses, search for new biomarkers and developing of companion diagnostics such as techniques for therapy evaluation and prognosis prediction.

Certifications

PageTop